Richard A Furie (Richard Furie)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 34

Top Topics

Disease Activity

Tyrosine Kinase

Systemic Lupus Erythematosus

Top Venues

Lupus science & medicine

Arthritis & rheumatology (Hoboken, N.J.)

Annals of the rheumatic diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Scott R P McDonnell, Van Anh Nguyen, Noah M Walton, Carsten Merkwirth, Feng Hong, Deborah Berg, Elena Tomaselli Muensterman, Richard A Furie
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus science & medicine 11 (1) (2024)
Scott R P McDonnell, Van Anh Nguyen, Noah M Walton, Carsten Merkwirth, Feng Hong, Deborah Berg, Elena Tomaselli Muensterman, Richard A Furie
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus science & medicine 11 (1) (2024)
Cynthia Aranow, Cornelia F Allaart, Zahir Amoura, Ian N Bruce, Patricia C Cagnoli, Walter W Chatham, Kenneth L Clark, Richard A Furie, James Groark, Murray B Urowitz, Ronald F Van Vollenhoven, Mark Daniels, Norma Lynn Fox, Yun Irene Gregan, Robert B Henderson, André van Maurik, Josephine C Ocran-Appiah, Mary Oldham, David A Roth, Don Shanahan, Paul P Tak, Y K Onno Teng
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Annals of the rheumatic diseases (2024)
Scott R P McDonnell, Van Anh Nguyen, Noah M Walton, Carsten Merkwirth, Feng Hong, Deborah Berg, Elena Tomaselli Muensterman, Richard A Furie
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus science & medicine 11 (1) (2024)
Scott R P McDonnell, Van Anh Nguyen, Noah M Walton, Carsten Merkwirth, Feng Hong, Deborah Berg, Elena Tomaselli Muensterman, Richard A Furie
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus science & medicine 11 (1) (2024)
Scott R P McDonnell, Van Anh Nguyen, Noah M Walton, Carsten Merkwirth, Feng Hong, Deborah Berg, Elena Tomaselli Muensterman, Richard A Furie
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus science & medicine 11 (1) (2024)
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang-Cheol Bae, John Boletis, Ian N Bruce, Ricard Cervera, Andrea Doria, Thomas Dörner, Richard A Furie, Dafna D Gladman, Frederic A Houssiau, Luís Sousa Inês, David R W Jayne, Marios Kouloumas, László Kovács, Chi Chiu Mok, Eric F Morand, Gabriella Moroni, Marta Mosca, Johanna Mucke, Chetan B Mukhtyar, György Nagy, Sandra Navarra, Ioannis Parodis, José M Pego-Reigosa, Michelle A Petri, Bernardo A Pons-Estel, Matthias Schneider, Josef S Smolen, Elisabet Svenungsson, Yoshiya Tanaka, Maria G G Tektonidou, Y K Onno Teng, Angela Tincani, Edward M Vital, Ronald F Van Vollenhoven, Chris Wincup, George K Bertsias, Dimitrios T Boumpas
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the rheumatic diseases (2023)
Laurent Arnaud, Richard A Furie, Eric F Morand, Martin Aringer, Christine Peschken, Barnabas Desta, Eleni Rapsomaniki, Jonatan Hedberg, Jacob Knagenhjelm, Caroline Seo, Tina Grünfeld Eén, Alessandro Sorrentino, Raj Tummala, Heide A Stirnadel-Farrant, Bo Ding
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature. Lupus science & medicine 10 (2) (2023)
David R W Jayne, Brad H Rovin, Eduardo Mysler, Richard A Furie, Frederic A Houssiau, Teodora Trasieva, Jacob Knagenhjelm, Erik Schwetje, Weifeng Tang, Raj Tummala, Catharina Lindholm
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus science & medicine 10 (2) (2023)
Laurent Arnaud, Richard A Furie, Eric F Morand, Martin Aringer, Christine Peschken, Barnabas Desta, Eleni Rapsomaniki, Jonatan Hedberg, Jacob Knagenhjelm, Caroline Seo, Tina Grünfeld Eén, Alessandro Sorrentino, Raj Tummala, Heide A Stirnadel-Farrant, Bo Ding
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature. Lupus science & medicine 10 (2) (2023)
Eric F Morand, Gabriel Abreu, Richard A Furie, Vera Golder, Raj Tummala
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Annals of the rheumatic diseases (2023)
Laurent Arnaud, Richard A Furie, Eric F Morand, Martin Aringer, Christine Peschken, Barnabas Desta, Eleni Rapsomaniki, Jonatan Hedberg, Jacob Knagenhjelm, Caroline Seo, Tina Grünfeld Eén, Alessandro Sorrentino, Raj Tummala, Heide A Stirnadel-Farrant, Bo Ding
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature. Lupus science & medicine 10 (2) (2023)
Laurent Arnaud, Richard A Furie, Eric F Morand, Martin Aringer, Christine Peschken, Barnabas Desta, Eleni Rapsomaniki, Jonatan Hedberg, Jacob Knagenhjelm, Caroline Seo, Tina Grünfeld Eén, Alessandro Sorrentino, Raj Tummala, Heide A Stirnadel-Farrant, Bo Ding
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature. Lupus science & medicine 10 (2) (2023)
Young Min Cho, Richard A Furie
The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus. Immunotherapy (2023)
David R W Jayne, Jürgen Steffgen, Juanita Romero-Diaz, Ingeborg Bajema, Dimitrios T Boumpas, Kajohnsak Noppakun, Hirofumi Amano, Harold Michael Gomez, Bancha Satirapoj, Yingyos Avihingsanon, Ratana Chawanasuntorapoj, Magdalena Madero, Beata Naumnik, Rhona Recto, Nora Fagan, Ivette Revollo, Jing Wu, Sudha Visvanathan, Richard A Furie
Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled, phase II trial. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Brad H Rovin, Richard A Furie, Jorge A Ross Terres, Sophia Giang, Thomas Schindler, Armando Turchetta, Jay P Garg, William F Pendergraft, Ana Malvar
Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Laurent Arnaud, Richard A Furie, Eric F Morand, Martin Aringer, Christine Peschken, Barnabas Desta, Eleni Rapsomaniki, Jonatan Hedberg, Jacob Knagenhjelm, Caroline Seo, Tina Grünfeld Eén, Alessandro Sorrentino, Raj Tummala, Heide A Stirnadel-Farrant, Bo Ding
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature. Lupus science & medicine 10 (2) (2023)
Anca D Askanase, Richard A Furie
A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus. Advances in therapy 39 (7) (2022)
Richard A Furie, Brad H Rovin, Frédéric Houssiau, Gabriel Contreras, Y K Onno Teng, Paula Curtis, Yulia Green, Mohamed Okily, Anuradha Madan, David A Roth
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study. Clinical journal of the American Society of Nephrology : CJASN 17 (11) (2022)
Ian N Bruce, Richard A Furie, Eric F Morand, Susan Manzi, Yoshiya Tanaka, Kenneth C Kalunian, Joan T Merrill, Patricia Puzio, Emmanuelle Maho, Christi Kleoudis, Marius Albulescu, Micki Hultquist, Raj Tummala
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the rheumatic diseases 81 (7) (2022)
Richard A Furie, Douglas R Hough, Allison Gaudy, Ying Ye, Shimon Korish, Nikolay Delev, Michael Weiswasser, Xiaojiang Zhan, Peter H Schafer, Victoria P Werth
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus science & medicine 9 (1) (2022)
Erik W Anderson, Ying Jin, Andrew Shih, Arnon Arazi, Sara Goodwin, Julien Roeser, Richard A Furie, Cynthia Aranow, Bruce Volpe, Betty Diamond, Meggan Mackay
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. Lupus science & medicine 9 (1) (2022)
David Jayne, Brad Rovin, Eduardo F Mysler, Richard A Furie, Frederic A Houssiau, Teodora Trasieva, Jacob Knagenhjelm, Erik Schwetje, Yen Lin Chia, Raj Tummala, Catharina Lindholm
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Annals of the rheumatic diseases 81 (4) (2022)
Kenneth C Kalunian, Richard A Furie, Eric F Morand, Ian N Bruce, Susan Manzi, Yoshiya Tanaka, Kevin L Winthrop, Ihor Hupka, Lijin Jinny Zhang, Shanti Werther, Gabriel Abreu, Micki Hultquist, Raj Tummala, Catharina Lindholm, Hussein Al-Mossawi
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) (2022)
Ronald F Van Vollenhoven, Anca D Askanase, Andrew S Bomback, Ian N Bruce, Angela Carroll, Maria Dall'Era, Mark Daniels, Roger Abramino Levy, Andreas Schwarting, Holly A Quasny, Murray B Urowitz, Ming-Hui Zhao, Richard A Furie
Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus science & medicine 9 (1) (2022)
Peter E Lipsky, Ronald van Vollenhoven, Thomas Dörner, Victoria P Werth, Joan T Merrill, Richard A Furie, Milan Petronijevic, Benito Velasco Zamora, Maria Majdan, Fedra Irazoque-Palazuelos, Robert Terbrueggen, Nikolay Delev, Michael Weiswasser, Shimon Korish, Mark Stern, Sarah Hersey, Ying Ye, Allison Gaudy, Zhaohui Liu, Robert Gagnon, Shaojun Tang, Peter H Schafer
Biological impact of iberdomide in patients with active systemic lupus erythematosus. Annals of the rheumatic diseases (2022)
Ellen Ginzler, Luiz Sergio Guedes Barbosa, David D'Cruz, Richard A Furie, Kathleen Maksimowicz-McKinnon, James Oates, Mittermayer Barreto Santiago, Amit Saxena, Saira Z Sheikh, Damon L Bass, Susan W Burriss, Jennifer A Gilbride, James G Groark, Michelle Miller, Amy Pierce, David A Roth, Beulah Ji
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) (2021)
Hermine I Brunner, Carlos Abud Mendoza, Masaaki Mori, Clarissa A Pilkington, Reema Syed, Syuji Takei, Diego O Viola, Richard A Furie, Sandra V Navarra, Fengchun Zhang, Damon L Bass, Gina Eriksson, Anne E Hammer, Beulah N Ji, Mohamed Okily, David A Roth, Holly A Quasny, Nicolino Ruperto
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD open 7 (3) (2021)
Richard A Furie, Eric F Morand, Ian N Bruce, David Alan Isenberg, Ronald van Vollenhoven, Gabriel Abreu, Lilia Pineda, Raj Tummala
What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. Arthritis & rheumatology (Hoboken, N.J.) 73 (11) (2021)
Richard A Furie, Ian N Bruce, Thomas Dörner, Manuel Gustavo Leon, Piotr Leszczyński, Murray Urowitz, Birgit Haier, Teri Jimenez, Claire Brittain, Jiajun Liu, Catherine Barbey, Christian Stach
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford, England) 60 (11) (2021)
Erik W Anderson, Joanna Fishbein, Joseph Hong, Julien Roeser, Richard A Furie, Cynthia Aranow, Bruce T Volpe, Betty Diamond, Meggan Mackay
Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus. Lupus science & medicine 8 (1) (2021)
W Winn Chatham, Richard A Furie, Amit Saxena, Philip Brohawn, Erik Schwetje, Gabriel Abreu, Raj Tummala
Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study. Arthritis & rheumatology (Hoboken, N.J.) 73 (5) (2021)
David Alan Isenberg, Richard A Furie, Nicholas S Jones, Pascal Guibord, Joshua Galanter, Chin Lee, Anna McGregor, Balazs Toth, Julie Rae, Olivia Hwang, Rupal Desai, Armend Lokku, Nandhini Ramamoorthi, Jason A Hackney, Pedro Miranda, Viviane A de Souza, Juan J Jaller-Raad, Anna Maura Fernandes, Garcia-Salinas Rodrigo, Leslie W Chinn, Michael J Townsend, Alyssa M Morimoto, Katie Tuckwell
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.) 73 (10) (2021)
Daniel J Wallace, Ellen M Ginzler, Joan T Merrill, Richard A Furie, William Stohl, W Winn Chatham, Arthur Weinstein, James D McKay, W Joseph McCune, Michelle A Petri, James Fettiplace, David A Roth, Beulah N Ji, Amy Heath
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 71 (7) (2019)